Ozempic Vs Jardiance For Diabetes And Weight Loss

Ozempic Vs Jardiance compares the efficacies of once-weekly injectable Semaglutide and Empagliflozin in lowering A1C, blood glucose, and body weight, and in patients with heart failure and kidney diseases.

Ozempic is a highly potent once-weekly injectable medicine indicated for the treatment of diabetes. It is especially indicated for obese diabetic patients with cardiovascular disease and uncontrolled blood glucose despite metformin.

Jardiance is a once-daily oral SGLT2 inhibitor that has been approved by the FDA for the treatment of Type 2 Diabetes Mellitus and heart failure.

It has also been approved for non-diabetic patients with heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF).

Try Our Premium Berberine Tea from Amazon

Ozempic Vs Jardiance: General Comparision:

Ozempic and Jardiance are both medications indicated for the treatment of diabetes. However, they belong to different classes of medicines:

Ozempic: GLP-1 analog
Jardiance: SGLT2 Inhibitor

Ozempic vs Jardiance comparison is tabulated below.

Feature	Ozempic	Jardiance
Active Ingredient	Semaglutide	Empagliflozin
Mechanism of Action	Stimulates insulin secretion and suppresses glucagon release. Delays gastric emptying. Causes satiety	Blocks the reabsorption of glucose by the kidneys.
Administration	Once-weekly subcutaneous injection	Oral tablet once daily
FDA-Approved Indications	Type 2 diabetes	Type 2 diabetes Heart failure
Dosage Forms and Strengths	Prefilled injection pen: 0.25mg, 0.5mg, and 1mg	Oral tablets: 10mg and 25mg
Half-Life	5-7 days	12.4 hours
Potential Side Effects	Nausea, vomiting, diarrhea, constipation, injection site reactions, pancreatitis, and risk of thyroid C-cell tumors	Urinary tract infections, genital yeast infections, hypotension, dehydration, Euglycemic ketoacidosis, increased risk of lower limb amputations, and fractures.
Contraindications	Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (multiple endocrine neoplasia syndrome type 2) DKA Hypoglycemia	ESRD or Severe renal impairment (eGFR <30 mL/min/1.73 m2) DKA

Jardiance is also available in combination with other medications including:

Metformin: Synjardy
Linagliptin: Glyxambi
Metformin and Linagliptin: TriJardy Xr

Ozempic Vs Jardiance: Which drug is more effective for Diabetes and Weight Loss:

Ozempic is considered the most potent diabetes medication, second only to Tirzepatide as per the ADA 2023 guidelines.

SGLT2 inhibitors including Jardiance have been labeled as diabetes drugs of “Intermediate potency” by the ADA 2023 recommendations. However, they are considered to be more potent than DPP-IV inhibitors.

In clinical trials, Ozempic has been proven to be more effective than Jardiance. The table below compares the efficacies of Ozmepic and Jardiance in lowering A1C and body weight:

Feature	Ozempic	Jardiance
A1C Reduction	1.0%-1.8%	0.5%-1.0%
Weight Loss	5%-10% of the baseline body weight.	2%-4% of the baseline body weight.

Ozempic has an A1C lowering effect almost double that of Jardiance. Similarly, the weight loss effects of Ozempic are also 2 to 3 times greater than that of Jardiance.

Effect of Ozempic Vs Jardiance on Blood Glucose:

Ozempic lowers both fasting and prandial blood glucose as a result of its insulin-secretory effects. However, Jardiance has a greater effect on fasting blood glucose than prandial blood glucose.

Here is a table comparing the effects of Jardiance Vs Ozempic on blood glucose and insulin requirements:

Feature	Ozempic	Jardiance
Fasting Blood Glucose	The mean change from baseline in fasting plasma glucose: -31 mg/dL with Ozempic 1 mg, and -35.5 mg/dL with Ozempic 0.5 mg.	The mean change from baseline in fasting plasma glucose levels was: -17.9 mg/dL with Jardiance 10 mg, and -17.3 mg/dL with Jardiance 25 mg.
Prandial Blood Glucose	The mean change from baseline in 2-hour postprandial glucose levels was: -56.5 mg/dL with Ozempic 1 mg, and -60.5 mg/dL with Ozempic 0.5 mg.	Not studied
A1C Reduction	Average A1C reduction: 1.0%-1.8%	Average A1C reduction: 0.5%-1.0% In clinical trials: -0.6% with Jardiance 10 mg, and -0.7% with Jardiance 25 mg.
Insulin Requirements	Reduces insulin requirements: 23.9% of patients treated with Ozempic 1 mg Vs 10.4% of patients were treated with a placebo.	Does not significantly impact insulin requirements.
Hypoglycemia	Does not cause hypoglycemia but there is a risk if used in combination with insulin and sulfonylureas	The risk of hypoglycemia is minimal.

It is important to note that both Ozempic and Jardiance do not cause hypoglycemia. Jardiance in particular is not associated with hypoglycemia even if used in combination with insulin or sulfonylureas.

Ozempic Vs Jardiance in Heart failure and Kidney disease:

Both Ozempic and Jardiance have been proven to improve the outcomes of patients with heart failure and kidney diseases.

Ozmepic is considered to be superior to Jardiance in reducing the risks of atherosclerotic cardiovascular diseases and stroke.

On the other hand, Jardiance is superior in patients with heart failure. Because of its superior efficacy, it has been approved for heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF).

Here is a table comparing the efficacies of Ozempic and Jardiance in patients with cardiovascular diseases:

Feature	Ozempic	Jardiance
Cardiovascular Effects	Trial: SUSTAIN 6 trialPatients: T2DM and high cardiovascular risk Outcome: Cardiovascular safety Results: 26% reduction in the risk of major adverse cardiovascular events (MACE) (primarily stroke)	Trial: EMPA-REG OUTCOME trialPatients: T2DM and established CVD Outcome: Cardiovascular safety Results: 14% reduction in the risk of MACE (primarily cardiovascular death)
Efficacy in Heart Failure	35% reduction in the risk of hospitalization due to heart failure compared to a placebo [Ref]	25% reduction in the risk of hospitalization due to heart failure compared to a placebo [Ref]
Hospitalization due to Heart Failure	Lower the risk of hospitalization due to heart failure by 35%	Lower the risk of hospitalization due to heart failure by 25%
Renal Outcomes	33% reduction in the risk of new or worsening nephropathy compared to placebo [Ref]	39% reduction in the risk of new or worsening nephropathy compared to placebo [Ref]50% reduction in the risk of kidney failure, dialysis, or kidney transplantation compared to a placebo [Ref]
Stroke	39% reduction in the risk of nonfatal stroke compared to placebo [Ref]	24% reduction in the risk of stroke compared to placebo [Ref]
Death	Significant reduction in the risk of all-cause mortality compared to placebo.	32% reduction in the risk of cardiovascular death and a 38% reduction in the risk of all-cause mortality compared to placebo [Ref]In the EMPEROR-Reduced trial, Jardiance was associated with a 27% reduction in the risk of cardiovascular death compared to placebo.

In conclusion:

Both Jardiance and Ozempic are potent drugs for the treatment of diabetes type 2. Ozmepic is more potent in lowering blood glucose and body weight.

Jardiance, on the other hand, is a better option for patients with heart failure and kidney disease.

Condition	Winner: Ozempic or Jardiance
Diabetes	Ozempic
Hypertension	Jardiance
Obesity	Ozempic
Atherosclerotic Cardiovascular diseases	Ozempic
Heart failure	Jardiance
Stroke	Ozempic
Kidney diseases	Jardiance